Long-term open-label safety study of galcanezumab in patients with episodic or chronic cluster headache. (October 2022)

• Record Type: Journal Article
• Authors: Riesenberg, Robert; Gaul, Charly; Stroud, Chad E; Dong, Yan; Bangs, Mark E; Wenzel, Richard; Martinez, James M; Oakes, Tina Myers
• Is Part Of: Cephalalgia. Volume 42:Number 11/12(2022)
• Page Start: 1225
• Page End: 1235
• Publication Date: 2022-10
• Subjects: Cluster headache -- headache disorder -- pain -- central nervous system disease -- galcanezumab -- CGRP; Headache -- Periodicals; 616.8491
• DOI: 10.1177/03331024221103509
• Languages: English
• ISSNs: 0333-1024

Abstract

Abstract: Background: CGAR, a Phase 3b open-label study, evaluated the long-term safety of galcanezumab in patients with cluster headache who completed one of two Phase 3 double-blind studies in chronic or episodic cluster headache. Methods: Patients (N = 164) received galcanezumab 300 mg subcutaneously up to once a month. Primary endpoint was safety, as assessed by treatment-emergent adverse events, serious adverse events, and suicidality. Other endpoints included discontinuation rates, immunogenicity, efficacy as assessed by the Patient Global Impression of Improvement, and health values. Results: At baseline, mean (standard deviation) age was 48.3 (9.8) years, 75.0% were men, and 85.4% were white. Treatment-emergent adverse events (n = 119 [72.6%]) were mostly mild-to-moderate, with nasopharyngitis the most commonly reported (22.0%). One of 18 serious adverse events was judged as treatment related (constipation). Two patients (1.2%) reported suicidal ideation. Five patients (3.1%) discontinued due to an adverse event. Eight patients were treatment-emergent anti-drug antibody positive, two of whom were not treatment-emergent anti-drug antibody positive in the parent studies. On the Patient Global Impression of Improvement, ≥81% reported their cluster headache status as very much, much, or a little better at Months 1, 6, and 12. Health value scores generally improved from baseline. Conclusions: In this open-label study, galcanezumab was generally well tolerated and improved patient-reported cluster headache status. Trial registration number: NCT02797951;https://clinicaltrials.gov/ct2/show/NCT02797951